Fractyl Health Inc., a metabolic therapeutics company, has announced advancements in its Rejuva Smart GLP-1 pancreatic gene therapy platform, specifically with its clinical candidate RJVA-001 targeting type 2 diabetes (T2D). The company revealed new preclinical data at the American Diabetes Association's 85th Scientific Sessions, demonstrating that a single dose of Rejuva was well-tolerated in healthy mice and effectively prevented obesity and diabetes in models exposed to a high-fat diet. These findings support the progression of RJVA-001 toward first-in-human studies, with preliminary clinical data expected in 2026, pending regulatory authorization. The study results have already been presented.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.